<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684981</url>
  </required_header>
  <id_info>
    <org_study_id>1160.249</org_study_id>
    <nct_id>NCT02684981</nct_id>
  </id_info>
  <brief_title>Patient Convenience Study (RE-SONANCE)</brief_title>
  <official_title>Non-interventional Study Describing Patients´ Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamine K Antagonist for Stroke Prevention in Non-Valvular Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of this non-interventional study is to describe patient's perception of anticoagulant
      treatment when using Pradaxa to prevent stroke and systemic embolism while suffering from
      atrial fibrillation (according to its approved indication in the approved dosages of 110
      milligrams or 150 milligrams twice daily) in comparison to standard care using Vitamin K
      Antagonist (VKA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 11, 2015</start_date>
  <completion_date type="Actual">June 1, 2017</completion_date>
  <primary_completion_date type="Actual">June 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Convenience PACT-Q2 Scores at Second and Last Assessment Compared to Baseline Assessment</measure>
    <time_frame>From baseline up to 210 days</time_frame>
    <description>The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfaction PACT-Q2 Scores at Second and Last Assessment Compared to Baseline Assessment</measure>
    <time_frame>From baseline up to 210 days</time_frame>
    <description>The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Convenience PACT-Q2 Scores at Second and Last Assessment Between Treatment Groups</measure>
    <time_frame>Day 30 up to Day 210</time_frame>
    <description>The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfaction PACT-Q2 Scores at Second and Last Assessment Between Treatment Groups</measure>
    <time_frame>Day 30 up to Day 210</time_frame>
    <description>The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterization of Patients With Respect to Congestive Heart Failure, Hypertension, Age (≥75), Diabetes Mellitus, Stroke/Transient Ischemic Attack (TIA), Vascular Disease, Age 65-75, Sex Category (CHA2DS2-VASc) Score</measure>
    <time_frame>Baseline</time_frame>
    <description>CHA2DS2-VASc score, are clinical prediction rules for estimating the risk of stroke in patients with non-rheumatic atrial fibrillation (AF), a common and serious heart arrhythmia associated with thromboembolic stroke. Such a score is used to determine whether or not treatment is required with anticoagulation therapy or antiplatelet therapy. CHA2DS2-VASc stroke risk score may range from 0 to 9 with 0 being the best outcome. Score of &lt; 2 was considered as low or intermediate risk and score of ≥ 2 was considered as high risk.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterization of Patients With Respect to Hypertension, Abnormal Renal and Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio (INR), Elderly (&gt;65 Years), Drug and Alcohol (HAS-BLED) Score</measure>
    <time_frame>Baseline</time_frame>
    <description>HAS-BLED is a scoring system developed to assess 1-year risk of major bleeding in patients with atrial fibrillation. A calculated HAS-BLED score is between 0 and 9 and based on eight parameters with a weighted value of 0-2. A high score corresponds to a greater risk, while low score corresponds to a lower risk. Data presented are percentage of patients with high and low risk.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterization of Patients With Respect to Kidney Function (Creatinine Clearance)</measure>
    <time_frame>Baseline and up to 210 days</time_frame>
    <description>Creatinine is a waste product produced by muscles from the breakdown of a compound called creatine. Creatinine is filtered from the blood by the kidneys and released into the urine. A creatinine clearance test measures creatinine levels in both a sample of blood and a sample of urine from a 24-hour urine collection. The results are used to calculate the amount of creatinine that has been cleared from the blood and passed into the urine. Data presented here are geometric mean and confidence interval of creatinine clearance for patients at baseline (V1), initiation stage (V2) and continuation stage (V3).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterization of Patients With Respect to Comorbidities</measure>
    <time_frame>Baseline</time_frame>
    <description>Comorbidity is the presence of one or more additional diseases or disorders co-occurring with (that is, concomitant or concurrent with) a primary disease or disorder. Data presented here are percentage of total patients with comorbidities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterization of Patients With Respect to Concomitant Therapies</measure>
    <time_frame>Baseline</time_frame>
    <description>Concomitant therapies are two or more drugs used or given at or almost at the same time. The data presented here are percentage of total patients for taking concomitant medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterization of Patients With Respect to Dosing of Pradaxa</measure>
    <time_frame>Baseline and up to 210 days</time_frame>
    <description>The data presented in this outcome measure is percentage of patients in both cohorts receiving 110 mg and 150 mg dose of Pradaxa at baseline (V1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration in Months of Previous VKA Treatment</measure>
    <time_frame>Baseline</time_frame>
    <description>The data presented in this outcome measure are Mean (SD) of duration in months of previous VKA treatment in total patients in cohort A.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke- and/or Bleeding Related Risk Factors in Medical History and at Baseline (Not Applicable)</measure>
    <time_frame>Baseline</time_frame>
    <description>This endpoint is not assessable as the necessary data was not collected in the database</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PACT-Q2 Scores at Last Assessment Compared to Second Assessment</measure>
    <time_frame>From 30 days up to 210 days</time_frame>
    <description>The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. Due to the non-normality of the data, results presented here are median change in PACT-Q2 scores between initiation stage (V2) and Continuation stage (V3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of PACT-Q1 Items at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Patients in Cohort B were given PACT-Q1 to assess patients` expectation from Anticoagulation therapy. Following are the seven items from PACT-Q1. The score range is 1-5. Each question is analyzed individually, with higher score indicating better outcome. A1 - How confident are you that your anticoagulant treatment (AT) will prevent blood clots? A2 - Do you expect that your AT will relieve some of the symptoms you experience? A3 - Do you expect that your AT will cause side effects such as minor bruises or bleeding? A4 - How important is it for you to have an AT that is easy to take? A5 - How concerned are you about making mistakes when taking your AT? A6 - How important is it for you to take care of your AT by yourself? A7 - How concerned are you about how much you may have to pay for your AT? For questions A1, A2, A4 and A6, higher score is higher expectations of the treatment and for questions A3, A5 and A7, lower score is higher expectations of the treatment.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">9472</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Cohort A - VKA to Pradaxa switcher</arm_group_label>
    <description>Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B - newly assigned to treatment</arm_group_label>
    <description>Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        European patients with non valvular atrial fibrillation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        Cohort A:

          1. A. Written informed consent prior to participation

          2. A. Female and male patients &gt;= 18 years of age with a diagnosis of non-valvular atrial
             fibrillation.

          3. A. At least 3 months of continuous VKA treatment for stroke prevention prior to
             baseline assessment.

          4. A. Patients switched to Pradaxa according Summary of Product Characteristics and
             physician`s discretion.

        OR

        Cohort B:

          1. B. Written informed consent prior to participation.

          2. B. Female and male patients &gt;= 18 years of age newly diagnosed with non-valvular
             atrial fibrillation and no previous treatment for stroke prevention (no use of any
             oral anticoagulant (OAC) within one year prior to enrolment).

          3. B. Stroke prevention treatment initiated with Pradaxa or VKA according to Summary of
             Product Characteristics and physician`s discretion.

        Exclusion criteria:

          1. Contraindication to the use of Pradaxa or VKA as described in the Summary of Product
             Characteristics (SmPC).

          2. Patients receiving Pradaxa or VKA for any other condition than stroke prevention in
             atrial fibrillation.

          3. Current participation in any clinical trial of a drug or device.

          4. Current participation in an European registry on the use of oral anticoagulation in
             AF.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovenia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>February 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2016</study_first_posted>
  <results_first_submitted>May 31, 2018</results_first_submitted>
  <results_first_submitted_qc>May 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2019</results_first_posted>
  <last_update_submitted>May 22, 2019</last_update_submitted>
  <last_update_submitted_qc>May 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT02684981/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 23, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT02684981/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This is an observational study. Total 9472 patients with Non-Valvular Atrial Fibrillation (NVAF) were enrolled in the study using Vitamin K antagonist (VKA) therapy prior to being switched to Pradaxa® and newly diagnosed with NVAF and initiated Pradaxa® or VKA. Patients were followed up for observational period of approximately 6 months.</recruitment_details>
      <pre_assignment_details>All patients were screened for eligibility. All enrolled patients met all implemented inclusion/exclusion criteria. Out of 9472 enrolled patients, 7 patients with unknown study treatment were not included in the main analysis set. Total 9465 patients were included in the main analysis set and started the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort A</title>
          <description>Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included.</description>
        </group>
        <group group_id="P2">
          <title>Cohort B- Pradaxa®</title>
          <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy.</description>
        </group>
        <group group_id="P3">
          <title>Cohort B- VKA</title>
          <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4100"/>
                <participants group_id="P2" count="3179"/>
                <participants group_id="P3" count="2186"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3860"/>
                <participants group_id="P2" count="2969"/>
                <participants group_id="P3" count="2059"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="210"/>
                <participants group_id="P3" count="127"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Permanently discontinued the treatment</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="161"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion crteria with known assigned treatment information.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort A</title>
          <description>Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included.</description>
        </group>
        <group group_id="B2">
          <title>Cohort B- Pradaxa®</title>
          <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy.</description>
        </group>
        <group group_id="B3">
          <title>Cohort B- VKA</title>
          <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4100"/>
            <count group_id="B2" value="3179"/>
            <count group_id="B3" value="2186"/>
            <count group_id="B4" value="9465"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4100"/>
                    <count group_id="B2" value="3179"/>
                    <count group_id="B3" value="2186"/>
                    <count group_id="B4" value="9465"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.5" spread="9.57"/>
                    <measurement group_id="B2" value="68.6" spread="10.1"/>
                    <measurement group_id="B3" value="68.5" spread="9.49"/>
                    <measurement group_id="B4" value="69.4" spread="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4100"/>
                    <count group_id="B2" value="3179"/>
                    <count group_id="B3" value="2186"/>
                    <count group_id="B4" value="9465"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1998"/>
                    <measurement group_id="B2" value="1602"/>
                    <measurement group_id="B3" value="1080"/>
                    <measurement group_id="B4" value="4680"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2102"/>
                    <measurement group_id="B2" value="1577"/>
                    <measurement group_id="B3" value="1106"/>
                    <measurement group_id="B4" value="4785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Convenience PACT-Q2 Scores at Second and Last Assessment Compared to Baseline Assessment</title>
        <description>The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.</description>
        <time_frame>From baseline up to 210 days</time_frame>
        <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Convenience PACT-Q2 Scores at Second and Last Assessment Compared to Baseline Assessment</title>
          <description>The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.</description>
          <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
          <units>Unit on scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median change from V1 to V2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3992"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.23" lower_limit="-67.3" upper_limit="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median change from V1 to V3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3827"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.08" lower_limit="-82.7" upper_limit="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for median change in PACT-Q2 scores from V1 to V2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon signed rank test has been used for this analysis</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for median change in convenience PACT-Q2 scores from V1 to V3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon signed rank test has been used for this analysis</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Satisfaction PACT-Q2 Scores at Second and Last Assessment Compared to Baseline Assessment</title>
        <description>The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.</description>
        <time_frame>From baseline up to 210 days</time_frame>
        <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction PACT-Q2 Scores at Second and Last Assessment Compared to Baseline Assessment</title>
          <description>The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.</description>
          <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
          <units>Unit on scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median change from V1 to V2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3992"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.86" lower_limit="-85.7" upper_limit="78.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median change from V1 to V3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3827"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.43" lower_limit="-57.1" upper_limit="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for median change in satisfaction PACT-Q2 scores from V1 to V2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon signed rank test has been used for this analysis</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for median change in satisfaction PACT-Q2 scores from V1 to V3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon signed rank test has been used for this analysis</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Convenience PACT-Q2 Scores at Second and Last Assessment Between Treatment Groups</title>
        <description>The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.</description>
        <time_frame>Day 30 up to Day 210</time_frame>
        <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort B- Pradaxa®</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B- VKA</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Convenience PACT-Q2 Scores at Second and Last Assessment Between Treatment Groups</title>
          <description>The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.</description>
          <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
          <units>Unit on scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3179"/>
                <count group_id="O2" value="2186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>V2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2817"/>
                    <count group_id="O2" value="2016"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.69" lower_limit="0.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="50.00" lower_limit="3.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2709"/>
                    <count group_id="O2" value="1944"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.54" lower_limit="15.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="59.62" lower_limit="0.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mean change in convenience PACT-Q2 scores between VKA and Pradaxa therapy at initiation stage (V2)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>18.377</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.514</dispersion_value>
            <estimate_desc>The primary analysis of PACT-Q2 scores was based on the random intercept model, where the matched group is considered as a random effect, the treatment as a fixed effect and the score as the response variable.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mean change in convenience PACT-Q2 scores between VKA and Pradaxa therapy at continuation stage (V3)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>23.341</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.509</dispersion_value>
            <estimate_desc>The primary analysis of PACT-Q2 scores was based on the random intercept model, where the matched group is considered as a random effect, the treatment as a fixed effect and the score as the response variable.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Satisfaction PACT-Q2 Scores at Second and Last Assessment Between Treatment Groups</title>
        <description>The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.</description>
        <time_frame>Day 30 up to Day 210</time_frame>
        <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort B- Pradaxa®</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B- VKA</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction PACT-Q2 Scores at Second and Last Assessment Between Treatment Groups</title>
          <description>The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. The PACT-Q2 is to be administered to patients once treatment is ongoing. Due to the non-normality of the data, results presented are for median change instead of mean change in PACT-Q2 scores from baseline (V1) to Initiation stage (V2) and from baseline (V1) to Continuation stage (V3) with full range instead of standard deviation of the differences.</description>
          <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
          <units>Unit on scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3179"/>
                <count group_id="O2" value="2186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>V2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2817"/>
                    <count group_id="O2" value="2016"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.86" lower_limit="0.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="50.00" lower_limit="0.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2709"/>
                    <count group_id="O2" value="1944"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.43" lower_limit="17.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="50.00" lower_limit="0.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mean change in satisfaction PACT-Q2 scores between VKA and Pradaxa therapy at initiation stage (V2)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>15.884</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.388</dispersion_value>
            <estimate_desc>The primary analysis of PACT-Q2 scores was based on the random intercept model, where the matched group is considered as a random effect, the treatment as a fixed effect and the score as the response variable.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mean change in satisfaction PACT-Q2 scores between VKA and Pradaxa therapy at continuation stage (V3)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>19.011</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.408</dispersion_value>
            <estimate_desc>The primary analysis of PACT-Q2 scores was based on the random intercept model, where the matched group is considered as a random effect, the treatment as a fixed effect and the score as the response variable.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characterization of Patients With Respect to Congestive Heart Failure, Hypertension, Age (≥75), Diabetes Mellitus, Stroke/Transient Ischemic Attack (TIA), Vascular Disease, Age 65-75, Sex Category (CHA2DS2-VASc) Score</title>
        <description>CHA2DS2-VASc score, are clinical prediction rules for estimating the risk of stroke in patients with non-rheumatic atrial fibrillation (AF), a common and serious heart arrhythmia associated with thromboembolic stroke. Such a score is used to determine whether or not treatment is required with anticoagulation therapy or antiplatelet therapy. CHA2DS2-VASc stroke risk score may range from 0 to 9 with 0 being the best outcome. Score of &lt; 2 was considered as low or intermediate risk and score of ≥ 2 was considered as high risk.</description>
        <time_frame>Baseline</time_frame>
        <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B- Pradaxa®</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy.</description>
          </group>
          <group group_id="O3">
            <title>Cohort B- VKA</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of Patients With Respect to Congestive Heart Failure, Hypertension, Age (≥75), Diabetes Mellitus, Stroke/Transient Ischemic Attack (TIA), Vascular Disease, Age 65-75, Sex Category (CHA2DS2-VASc) Score</title>
          <description>CHA2DS2-VASc score, are clinical prediction rules for estimating the risk of stroke in patients with non-rheumatic atrial fibrillation (AF), a common and serious heart arrhythmia associated with thromboembolic stroke. Such a score is used to determine whether or not treatment is required with anticoagulation therapy or antiplatelet therapy. CHA2DS2-VASc stroke risk score may range from 0 to 9 with 0 being the best outcome. Score of &lt; 2 was considered as low or intermediate risk and score of ≥ 2 was considered as high risk.</description>
          <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
          <units>Percentage of patients (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4100"/>
                <count group_id="O2" value="3179"/>
                <count group_id="O3" value="2186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High risk (Score &gt;= 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.3"/>
                    <measurement group_id="O2" value="87.8"/>
                    <measurement group_id="O3" value="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low risk (Score &lt; 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                    <measurement group_id="O2" value="8.2"/>
                    <measurement group_id="O3" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characterization of Patients With Respect to Hypertension, Abnormal Renal and Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio (INR), Elderly (&gt;65 Years), Drug and Alcohol (HAS-BLED) Score</title>
        <description>HAS-BLED is a scoring system developed to assess 1-year risk of major bleeding in patients with atrial fibrillation. A calculated HAS-BLED score is between 0 and 9 and based on eight parameters with a weighted value of 0-2. A high score corresponds to a greater risk, while low score corresponds to a lower risk. Data presented are percentage of patients with high and low risk.</description>
        <time_frame>Baseline</time_frame>
        <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B- Pradaxa®</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy.</description>
          </group>
          <group group_id="O3">
            <title>Cohort B- VKA</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of Patients With Respect to Hypertension, Abnormal Renal and Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio (INR), Elderly (&gt;65 Years), Drug and Alcohol (HAS-BLED) Score</title>
          <description>HAS-BLED is a scoring system developed to assess 1-year risk of major bleeding in patients with atrial fibrillation. A calculated HAS-BLED score is between 0 and 9 and based on eight parameters with a weighted value of 0-2. A high score corresponds to a greater risk, while low score corresponds to a lower risk. Data presented are percentage of patients with high and low risk.</description>
          <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
          <units>Percentage of patients (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4100"/>
                <count group_id="O2" value="3179"/>
                <count group_id="O3" value="2186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High risk (Score &gt;= 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2"/>
                    <measurement group_id="O2" value="29.1"/>
                    <measurement group_id="O3" value="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low risk (Score &lt; 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0"/>
                    <measurement group_id="O2" value="64.8"/>
                    <measurement group_id="O3" value="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7"/>
                    <measurement group_id="O2" value="6.8"/>
                    <measurement group_id="O3" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characterization of Patients With Respect to Kidney Function (Creatinine Clearance)</title>
        <description>Creatinine is a waste product produced by muscles from the breakdown of a compound called creatine. Creatinine is filtered from the blood by the kidneys and released into the urine. A creatinine clearance test measures creatinine levels in both a sample of blood and a sample of urine from a 24-hour urine collection. The results are used to calculate the amount of creatinine that has been cleared from the blood and passed into the urine. Data presented here are geometric mean and confidence interval of creatinine clearance for patients at baseline (V1), initiation stage (V2) and continuation stage (V3).</description>
        <time_frame>Baseline and up to 210 days</time_frame>
        <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B- Pradaxa</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy were included.</description>
          </group>
          <group group_id="O3">
            <title>Cohort B-VKA</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of Patients With Respect to Kidney Function (Creatinine Clearance)</title>
          <description>Creatinine is a waste product produced by muscles from the breakdown of a compound called creatine. Creatinine is filtered from the blood by the kidneys and released into the urine. A creatinine clearance test measures creatinine levels in both a sample of blood and a sample of urine from a 24-hour urine collection. The results are used to calculate the amount of creatinine that has been cleared from the blood and passed into the urine. Data presented here are geometric mean and confidence interval of creatinine clearance for patients at baseline (V1), initiation stage (V2) and continuation stage (V3).</description>
          <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
          <units>millilitre per minute (mL/min)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4100"/>
                <count group_id="O2" value="3179"/>
                <count group_id="O3" value="2186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>V1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3501"/>
                    <count group_id="O2" value="2721"/>
                    <count group_id="O3" value="1813"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.89" lower_limit="73.02" upper_limit="74.77"/>
                    <measurement group_id="O2" value="76.24" lower_limit="75.25" upper_limit="77.24"/>
                    <measurement group_id="O3" value="71.83" lower_limit="70.63" upper_limit="73.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1318"/>
                    <count group_id="O2" value="937"/>
                    <count group_id="O3" value="603"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.59" lower_limit="73.17" upper_limit="76.05"/>
                    <measurement group_id="O2" value="75.27" lower_limit="73.71" upper_limit="76.86"/>
                    <measurement group_id="O3" value="71.86" lower_limit="69.87" upper_limit="73.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1539"/>
                    <count group_id="O2" value="1070"/>
                    <count group_id="O3" value="686"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.82" lower_limit="71.61" upper_limit="74.05"/>
                    <measurement group_id="O2" value="74.24" lower_limit="72.81" upper_limit="75.69"/>
                    <measurement group_id="O3" value="71.79" lower_limit="69.98" upper_limit="73.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characterization of Patients With Respect to Comorbidities</title>
        <description>Comorbidity is the presence of one or more additional diseases or disorders co-occurring with (that is, concomitant or concurrent with) a primary disease or disorder. Data presented here are percentage of total patients with comorbidities.</description>
        <time_frame>Baseline</time_frame>
        <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B- Pradaxa®</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy.</description>
          </group>
          <group group_id="O3">
            <title>Cohort B- VKA</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of Patients With Respect to Comorbidities</title>
          <description>Comorbidity is the presence of one or more additional diseases or disorders co-occurring with (that is, concomitant or concurrent with) a primary disease or disorder. Data presented here are percentage of total patients with comorbidities.</description>
          <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
          <units>Percentage of patients (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4100"/>
                <count group_id="O2" value="3179"/>
                <count group_id="O3" value="2186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4"/>
                    <measurement group_id="O2" value="83.4"/>
                    <measurement group_id="O3" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characterization of Patients With Respect to Concomitant Therapies</title>
        <description>Concomitant therapies are two or more drugs used or given at or almost at the same time. The data presented here are percentage of total patients for taking concomitant medication.</description>
        <time_frame>Baseline</time_frame>
        <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B- Pradaxa®</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy.</description>
          </group>
          <group group_id="O3">
            <title>Cohort B- VKA</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of Patients With Respect to Concomitant Therapies</title>
          <description>Concomitant therapies are two or more drugs used or given at or almost at the same time. The data presented here are percentage of total patients for taking concomitant medication.</description>
          <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
          <units>Percentage of patients (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4100"/>
                <count group_id="O2" value="3179"/>
                <count group_id="O3" value="2186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4"/>
                    <measurement group_id="O2" value="83.4"/>
                    <measurement group_id="O3" value="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Characterization of Patients With Respect to Dosing of Pradaxa</title>
        <description>The data presented in this outcome measure is percentage of patients in both cohorts receiving 110 mg and 150 mg dose of Pradaxa at baseline (V1).</description>
        <time_frame>Baseline and up to 210 days</time_frame>
        <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of Patients With Respect to Dosing of Pradaxa</title>
          <description>The data presented in this outcome measure is percentage of patients in both cohorts receiving 110 mg and 150 mg dose of Pradaxa at baseline (V1).</description>
          <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
          <units>Percentage of patients (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4100"/>
                <count group_id="O2" value="3179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pradaxa 110 mg at V1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9"/>
                    <measurement group_id="O2" value="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pradaxa 150 mg at V1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.1"/>
                    <measurement group_id="O2" value="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration in Months of Previous VKA Treatment</title>
        <description>The data presented in this outcome measure are Mean (SD) of duration in months of previous VKA treatment in total patients in cohort A.</description>
        <time_frame>Baseline</time_frame>
        <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration in Months of Previous VKA Treatment</title>
          <description>The data presented in this outcome measure are Mean (SD) of duration in months of previous VKA treatment in total patients in cohort A.</description>
          <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.00" spread="39.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PACT-Q2 Scores at Last Assessment Compared to Second Assessment</title>
        <description>The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. Due to the non-normality of the data, results presented here are median change in PACT-Q2 scores between initiation stage (V2) and Continuation stage (V3).</description>
        <time_frame>From 30 days up to 210 days</time_frame>
        <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included.</description>
          </group>
        </group_list>
        <measure>
          <title>PACT-Q2 Scores at Last Assessment Compared to Second Assessment</title>
          <description>The individual questions in PACT-Q2 were grouped into two domains, convenience and satisfaction. For each domain, a global score was calculated and used for analysis. The range of the global score is 0-100, with higher score indicating better outcome. The global score is calculated by summing up the individual scores, and then rescaled to 0-100. Due to the non-normality of the data, results presented here are median change in PACT-Q2 scores between initiation stage (V2) and Continuation stage (V3).</description>
          <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information.</population>
          <units>Unit on scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Convenience PACT-Q2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3820"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" lower_limit="-80.8" upper_limit="82.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction PACT-Q2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3820"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" lower_limit="-57.1" upper_limit="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Median convenience and satisfaction PACT-Q2 scores at last assessment compared to second assessment</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon signed rank test has been used for this analysis</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stroke- and/or Bleeding Related Risk Factors in Medical History and at Baseline (Not Applicable)</title>
        <description>This endpoint is not assessable as the necessary data was not collected in the database</description>
        <time_frame>Baseline</time_frame>
        <population>Treated set (Necessary data was not collected in the data base)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B- Pradaxa®</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy.</description>
          </group>
          <group group_id="O3">
            <title>Cohort B- VKA</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke- and/or Bleeding Related Risk Factors in Medical History and at Baseline (Not Applicable)</title>
          <description>This endpoint is not assessable as the necessary data was not collected in the database</description>
          <population>Treated set (Necessary data was not collected in the data base)</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Description of PACT-Q1 Items at Baseline</title>
        <description>Patients in Cohort B were given PACT-Q1 to assess patients` expectation from Anticoagulation therapy. Following are the seven items from PACT-Q1. The score range is 1-5. Each question is analyzed individually, with higher score indicating better outcome. A1 - How confident are you that your anticoagulant treatment (AT) will prevent blood clots? A2 - Do you expect that your AT will relieve some of the symptoms you experience? A3 - Do you expect that your AT will cause side effects such as minor bruises or bleeding? A4 - How important is it for you to have an AT that is easy to take? A5 - How concerned are you about making mistakes when taking your AT? A6 - How important is it for you to take care of your AT by yourself? A7 - How concerned are you about how much you may have to pay for your AT? For questions A1, A2, A4 and A6, higher score is higher expectations of the treatment and for questions A3, A5 and A7, lower score is higher expectations of the treatment.</description>
        <time_frame>Baseline</time_frame>
        <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort B- Pradaxa®</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B- VKA</title>
            <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Description of PACT-Q1 Items at Baseline</title>
          <description>Patients in Cohort B were given PACT-Q1 to assess patients` expectation from Anticoagulation therapy. Following are the seven items from PACT-Q1. The score range is 1-5. Each question is analyzed individually, with higher score indicating better outcome. A1 - How confident are you that your anticoagulant treatment (AT) will prevent blood clots? A2 - Do you expect that your AT will relieve some of the symptoms you experience? A3 - Do you expect that your AT will cause side effects such as minor bruises or bleeding? A4 - How important is it for you to have an AT that is easy to take? A5 - How concerned are you about making mistakes when taking your AT? A6 - How important is it for you to take care of your AT by yourself? A7 - How concerned are you about how much you may have to pay for your AT? For questions A1, A2, A4 and A6, higher score is higher expectations of the treatment and for questions A3, A5 and A7, lower score is higher expectations of the treatment.</description>
          <population>Main Analysis set (MAS): This includes all eligible patients who met inclusion/exclusion criteria with known assigned treatment information</population>
          <units>Percentage of patients (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3179"/>
                <count group_id="O2" value="2186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A1- Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A1- Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A1- A little</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                    <measurement group_id="O2" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A1- Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A1- A lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8"/>
                    <measurement group_id="O2" value="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A1- Extremely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A2- Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A2- Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A2- A little</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A2- Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9"/>
                    <measurement group_id="O2" value="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A2- A lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9"/>
                    <measurement group_id="O2" value="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A2- Extremely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A3- Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A3- Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8"/>
                    <measurement group_id="O2" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A3- A little</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4"/>
                    <measurement group_id="O2" value="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A3- Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9"/>
                    <measurement group_id="O2" value="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A3- A lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A3- Extremely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A4- Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A4- Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A4- A little</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A4- Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A4- A lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1"/>
                    <measurement group_id="O2" value="53.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A4- Extremely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                    <measurement group_id="O2" value="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A5- Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A5- Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3"/>
                    <measurement group_id="O2" value="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A5- A little</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3"/>
                    <measurement group_id="O2" value="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A5- Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8"/>
                    <measurement group_id="O2" value="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A5- A lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2"/>
                    <measurement group_id="O2" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A5- Extremely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A6- Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A6- Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A6- A little</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A6- Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3"/>
                    <measurement group_id="O2" value="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A6- A lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6"/>
                    <measurement group_id="O2" value="49.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A6- Extremely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A7- Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A7- Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                    <measurement group_id="O2" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A7- A little</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A7- Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0"/>
                    <measurement group_id="O2" value="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A7- A lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A7- Extremely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration, until end of the study, up to 210 days.</time_frame>
      <desc>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment. The safety analysis set including all the patients with actual follow up were used for this analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort A</title>
          <description>Patients with Non-Valvular Atrial Fibrillation (NVAF) using Vitamin K Antagonist (VKA) therapy prior to being switched to oral dose of Pradaxa® 110 milligram (mg) and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) were included.</description>
        </group>
        <group group_id="E2">
          <title>Cohort B- Pradaxa®</title>
          <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) therapy.</description>
        </group>
        <group group_id="E3">
          <title>Cohort B- VKA</title>
          <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Vitamin K Antagonist (VKA) therapy were included.</description>
        </group>
        <group group_id="E4">
          <title>Cohort B</title>
          <description>Newly diagnosed patients with Non-Valvular Atrial Fibrillation (NVAF) and initiated Pradaxa® 110 mg and Pradaxa® 150 mg hard capsules twice daily containing Dabigatran etexilate (active ingredient: Dabigatran) or Vitamin K Antagonist (VKA) therapy were included.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="5345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Cardioversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Left atrial appendage occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Meningioma surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Vascular stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5345"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4066"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5345"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Improper dose reduction in patients not fulfilling reduction criteria, Selection bias, Missing data, Creatinine clearance in minimals, Antiarrhythmic medication contraindicated to Pradaxa, Unassessable Stroke/bleeding related risk factors endpoint</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

